Wilmington Pharmaceuticals is a biotechnology and healthcare startup founded in 2002. The company specializes in creating and licensing patient-friendly, fast-dissolving formulations for existing medicines, ultimately streamlining the FDA approval process and ensuring swift market entry for their partners. With a recent $1.30M Series B investment on 26 October 2006 from Wilmington Investor Network and Emergent Growth Fund, the company is poised for expansion and further development in the industry. Leveraging their unique capabilities, Wilmington Pharmaceuticals stands out as an ideal partner for innovative pharmaceutical development, contributing to regulatory optimization and financial success. While the company's headquarters location remains unspecified, this recent investment highlights their potential for growth and prominence in the healthcare sector.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $1.30M | 2 |
|
26 Oct 2006 |
No recent news or press coverage available for Wilmington Pharmaceuticals.
We care about your data, and we'd love to use cookies make your experience better.
